YOLFTbeta
Spero Therapeutics Inc

Spero Therapeutics Inc

SPRO · NASDAQ · Healthcare / Biotechnology

0.9999USD-0.00 (-0.01%)

Price History

Full chart

Market Stats

Previous Close1.00
Open1.04
Day Range0.9521 – 1.04
52-Week Range1.08 – 3.08
Volume357.47K
Market Cap71.63M
P/E (TTM)8.79
Forward P/E0.00
EPS0.14
Dividend Yield0.00%
Beta1.48
50-Day Avg1.23
200-Day Avg2.14

About

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Esther P. Rajavelu
  • Employees25
  • Headquarters675 Massachusetts Avenue, Cambridge, MA, United States, 02139, USA
  • Websitehttps://sperotherapeutics.com

Leadership

  • Ms. Esther P. RajaveluCEO, President, CFO, Chief Business Officer, Treasurer & Director · b. 1979
  • Mr. Timothy KeutzerChief Operating Officer · b. 1968
  • Mr. John RaymondSenior Vice President of Finance & Business Operations
  • Dr. Debra Jeske Zack M.D., Ph.D.Chief Medical Officer · b. 1957
  • Ms. Sheila FinanSenior VP & Controller

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0335.00K1.98M3.97M4.74M9.33M3.07M48.58M103.78M47.98M59.62M
Growth (%)--+490.75%+100.40%+19.57%+96.75%-67.10%+1482.38%+113.63%-53.77%+24.27%
Cost of Revenue11.00K26.33M32.87M33.88M65.78M67.00M1.12M1.55M51.44M96.76M-
Gross Profit-11.00K-26.00M1.98M3.97M4.74M9.33M3.07M48.58M52.34M-48.78M59.62M
Gross Margin--7760.60%100.00%100.00%100.00%100.00%100.00%100.00%50.43%-101.67%100.00%
Operating Expense13.32M7.22M43.71M46.77M67.96M88.44M91.04M90.78M30.86M24.58M59.64M
Operating Income-13.33M-33.22M-41.73M-42.81M-63.22M-79.11M-87.97M-42.20M21.48M-73.36M-24.00K
Operating Margin--9916.72%-2108.64%-1079.32%-1333.11%-847.94%-2865.50%-86.86%20.70%-152.91%-0.04%
EBITDA-13.32M-32.94M-41.37M-42.40M-62.47M-78.35M-87.17M-42.94M27.15M-72.48M8.83M
EBITDA Margin--9833.43%-2090.30%-1069.01%-1317.29%-839.79%-2839.41%-88.39%26.16%-151.08%14.82%
Net Income-10.15M-25.49M-46.10M-41.66M-60.17M-77.52M-89.76M-46.41M22.81M-68.57M8.57M
Net Income Margin--7609.25%-2329.31%-1050.48%-1268.98%-830.86%-2923.65%-95.55%21.98%-142.91%14.38%
R&D11.13M26.33M32.87M33.88M65.78M67.00M64.53M47.59M51.44M96.76M38.47M
R&D as % of Total Revenue-7860.60%1660.89%854.39%1387.07%718.15%2101.82%97.97%49.57%201.67%64.52%
Interest Expense00303.00K303.00K001.94M2.60M0--
Interest Expense % of Total Revenue-0.00%15.31%7.64%0.00%0.00%63.19%5.36%0.00%--

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets7.18M13.77M93.48M129.01M106.10M153.45M171.07M124.80M182.39M110.54M68.92M
Total Liabilities7.43M7.41M8.52M13.15M31.53M21.41M82.78M48.87M75.50M64.42M9.90M
Total Equity196.00K10.17M84.96M115.86M74.57M132.04M88.29M75.93M106.89M46.12M59.02M
Cash5.69M10.31M87.29M34.08M29.73M85.21M112.58M109.11M76.33M52.89M40.27M
Total Debt----5.54M7.84M7.33M6.65M5.54M4.30M2.90M
Net Debt-5.69M-10.31M-87.29M-34.08M-24.18M-77.37M-105.25M-102.46M-70.79M-48.59M-37.37M

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-9.61M-28.96M-39.11M-39.63M-50.02M-85.87M-64.35M-7.73M-32.99M-23.44M-12.62M
Investing Cash Flow-232.00K-830.00K-27.00K-83.16M29.53M10.47M7.67M33.81M---
Financing Cash Flow15.28M34.41M116.11M69.52M16.14M130.88M84.05M-29.55M221.00K0-
Capital Expenditure232.00K830.00K27.00K2.44M314.00K157.00K64.35M0000
Free Cash Flow-9.84M-29.79M-39.14M-42.06M-50.33M-86.03M-64.35M-7.73M-32.99M-23.44M-12.62M
Dividends Paid--0---47.48M54.48M---
FCF to OCF102.41%102.87%100.07%106.15%100.63%100.18%100.00%100.00%100.00%100.00%100.00%
Dividend Paid to FCF--0.00%----73.79%-704.76%---

Earnings

Report DateMay 4, 2017Aug 30, 2017Dec 14, 2017May 10, 2018Aug 9, 2018Nov 8, 2018Mar 14, 2019May 9, 2019Aug 8, 2019Nov 4, 2019Mar 16, 2020May 8, 2020Aug 6, 2020Nov 5, 2020Mar 11, 2021May 6, 2021Aug 5, 2021Nov 10, 2021Mar 31, 2022May 16, 2022Aug 10, 2022Nov 14, 2022Mar 30, 2023May 11, 2023Aug 10, 2023Nov 13, 2023Mar 13, 2024May 15, 2024Aug 5, 2024Nov 14, 2024Mar 11, 2025May 13, 2025Aug 12, 2025Nov 13, 2025Mar 27, 2026May 14, 2026Aug 12, 2026Nov 12, 2026
EPS Estimate0.000.00-35.07-1.20-0.77-0.63-0.75-0.77-0.86-0.85-1.08-1.25-1.13-0.89-0.74-0.63-0.75-0.66-0.75-0.95-0.93-0.240.04-0.26-0.37-0.03-0.10-0.06-0.38-0.36-0.31-0.44-0.38-0.25---0.19-0.14
EPS Actual-0.51-2.96-36.02-0.74-0.69-0.60-0.60-0.29-0.74-0.95-1.36-1.19-0.85-0.86-0.68-0.66-0.63-0.70-0.90-1.01-0.43-0.330.55-0.25-0.230.040.96-0.24-0.33-0.32-0.37-0.25-0.03-0.130.53-0.13-0.16-
Surprise---2.71%38.33%10.39%4.76%20.00%62.34%13.95%-11.76%-25.93%4.80%24.78%3.37%8.11%-4.76%16.00%-6.06%-20.00%-6.32%53.76%-37.50%1275.00%3.85%37.84%233.33%1060.00%-300.00%13.16%11.11%-18.35%43.18%92.11%48.00%--15.79%-
Timing--After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours--After-hoursAfter-hours

Key Statistics & Ratios

Market Cap71.63M
Enterprise Value24.94M
Trailing P/E8.79
Forward P/E0.00
PEG Ratio0.00
Price / Sales1.52
Price / Book1.67
EPS0.14
Book Value0.76
Revenue (TTM)47.00M
Gross Profit (TTM)26.46M
EBITDA7.16M
Profit Margin15.71%
Operating Margin14.07%
Return on Equity19.17%
Return on Assets7.19%
Shares Outstanding58.23M
Shares Float46.72M
Beta1.48
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 3 analystsTarget 5.00
  • Buy
    1
  • Hold
    2

Ownership Breakdown

Institutions
18.22%
Insiders
22.61%
Retail / Other
59.17%

Top Institutional Holders

  • GSK PLC
    9.19M15.78%
  • Pfizer Inc
    2.36M4.06%
  • Vanguard Capital Management, LLC
    1.80M3.09%
  • Renaissance Technologies Corp
    1.19M2.04%
  • Alphabet Inc
    889.98K1.53%
  • Geode Capital Management, LLC
    519.92K0.89%
  • BlackRock Inc
    433.20K0.74%
  • Two Sigma Investments LLC
    382.81K0.66%
  • Susquehanna International Group, LLP
    333.12K0.57%
  • GSA Capital Partners LLP
    285.91K0.49%
  • Dimensional Fund Advisors, Inc.
    274.82K0.47%
  • Vanguard Fiduciary Trust Co
    264.12K0.45%
  • State Street Corp
    214.75K0.37%
  • Squarepoint Ops LLC
    194.30K0.33%
  • Marshall Wace Asset Management Ltd
    157.07K0.27%
  • Northern Trust Corp
    120.98K0.21%
  • Bridgeway Capital Management, LLC
    114.80K0.20%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.40M2.40%
  • Fidelity Extended Market Index
    248.94K0.43%
  • iShares Micro-Cap ETF
    150.21K0.26%